InSite Vision to Vigorously Defend AzaSite®
Patents
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 5, 2012--
InSite Vision Incorporated (OTCBB:INSV) today announced that the
University of California, San Francisco (UCSF) has appealed the judgment
of the United States Patent and Trademark Office (USPTO) panel that
found in favor of the Company in its patent interference litigation with
UCSF. The USPTO panel of judges entered judgment in favor of InSite
Vision and confirmed the inventorship of InSite Vision’s U.S. Patent
Nos. 6,239,113 and 6,569,443 protecting AzaSite® on November
25, 2011. The appeal was filed by UCSF with the U.S. Court of Appeals
for the Federal Circuit in Washington, D.C. on December 23, 2011.
“We are disappointed that UCSF has chosen to appeal the judgment of the
USPTO in this case,” said Timothy Ruane, InSite Vision's Chief Executive
Officer. “We strongly believe that the UCSF claims are entirely without
merit as confirmed by the USPTO and we will continue to vigorously
defend our position.”
In 2009, the Regents of the University of California claimed that the
inventions contained in the patents were made by a former employee of
the University alone and without collaboration with InSite Vision, the
assignee of all the named inventors.
About InSite Vision
InSite Vision is advancing new and superior ophthalmologic products for
unmet eye care needs. The company’s product portfolio utilizes InSite
Vision’s proven DuraSite® bioadhesive polymer core
technology, an innovative platform that extends the duration of drug
retention on the surface of the eye, thereby reducing frequency of
treatment and improving the efficacy of topically delivered drugs. The
DuraSite platform is currently leveraged in two commercial products for
the treatment of bacterial eye infections, AzaSite®
(azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck,
and Besivance® (besifloxacin ophthalmic suspension) 0.6%,
marketed by Bausch + Lomb. InSite Vision’s clinical-stage ophthalmic
product pipeline includes AzaSite Plus™ (ISV-502) and DexaSite™
(ISV-305) for the treatment of eye infections, BromSite™
(ISV-303) for pain and swelling associated with ocular surgery, and
ISV-101 for the treatment of dry eye disease. For further information on
InSite Vision, please visit www.insitevision.com.
Forward-looking Statements
This news release contains certain statements of a forward looking
nature relating to future events, including the Company’s plans with
respect to the litigation described above. Such statements entail a
number of risks and uncertainties, including but not limited to: the
inherent uncertainty of any litigation matter; the Company’s ability to
continue to adequately protect its intellectual property and to be free
to operate with regard to the intellectual property of others. Reference
is made to the discussion of these and other risk factors detailed in
InSite Vision's filings with the Securities and Exchange Commission,
including its annual report on Form 10-K and its quarterly reports on
Form 10-Q, under the caption "Risk Factors" and elsewhere in such
reports. Any forward-looking statements or projections are based on the
limited information currently available to InSite Vision, which is
subject to change. Although any such forward-looking statements or
projections and the factors influencing them will likely change, InSite
Vision undertakes no obligation to update the information. Such
information speaks only as of the date of its release. Actual events or
results could differ materially and one should not assume that the
information provided in this release is still valid at any later date.
AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb
Incorporated.
Source: InSite Vision Incorporated
InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial
Officer
mail@insite.com
or
Media
and Investor inquiries
BCC Partners
Michelle Corral,
415-794-8662
Karen L. Bergman, 650-575-1509
